PTK6 Antibody

說明書

中文名稱：

PTK6兔多克隆抗體
貨號：

CSB-PA997274
規格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA997274(PTK6 Antibody) at dilution 1/30, on the right is treated with fusion protein. (Original magnification: ×200)

The image on the left is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using CSB-PA997274(PTK6 Antibody) at dilution 1/30, on the right is treated with fusion protein. (Original magnification: ×200)
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

Q13882
基因名：

PTK6
別名：

Breast tumor kinase antibody; Breast tumour kinase antibody; Protein tyrosine kinase 6 antibody; Protein-tyrosine kinase 6 antibody; Ptk6 antibody; PTK6_HUMAN antibody; Tyrosine protein kinase BRK antibody; Tyrosine-protein kinase BRK antibody
宿主：

Rabbit
反應種屬：

Human,Mouse
免疫原：

Fusion protein of Human PTK6
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產品提供形式：

Liquid
應用范圍：

ELISA,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:2000-1:5000
IHC	1:25-1:100

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Non-receptor tyrosine-protein kinase implicated in the regulation of a variety of signaling pathways that control the differentiation and maintenance of normal epithelia, as well as tumor growth. Function seems to be context dependent and differ depending on cell type, as well as its intracellular localization. A number of potential nuclear and cytoplasmic substrates have been identified. These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1, KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B and a variety of signaling molecules: ARHGAP35/p190RhoGAP, PXN/paxillin, BTK/ATK, STAP2/BKS. Associates also with a variety of proteins that are likely upstream of PTK6 in various signaling pathways, or for which PTK6 may play an adapter-like role. These proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal or non-tumorigenic tissues, PTK6 promotes cellular differentiation and apoptosis. In tumors PTK6 contributes to cancer progression by sensitizing cells to mitogenic signals and enhancing proliferation, anchorage-independent survival and migration/invasion. Association with EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and growth through enhancement of EGF-induced signaling via BTK/AKT and PI3 kinase. Contributes to migration and proliferation by contributing to EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes association with RASA1/p120RasGAP, inactivating RhoA while activating RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation. Nuclear PTK6 may be important for regulating growth in normal epithelia, while cytoplasmic PTK6 might activate oncogenic signaling pathways.; Isoform 2 inhibits PTK6 phosphorylation and PTK6 association with other tyrosine-phosphorylated proteins.
基因功能參考文獻：
1. Using small molecule inhibitors, findings suggest that the kinase activity of PTK6 does not play a significant role in breast tumorigenesis. PMID: 29879184
2. These results indicate that plasma-membrane-associated PTK6 phosphorylates Eps8, which promotes cell proliferation, adhesion, and migration PMID: 28214294
3. Expression of PTK6 in established tumors may maintain the epithelial phenotype, preventing tumor progression. PMID: 26983689
4. analysis of recombinant PTK6 kinase domain by x-ray crystallography reveals details of its binding to inhibitors PMID: 27993680
5. The crystal structure of the kinase domain of human PTK6 has been reported. PMID: 27480927
6. PTK6 mRNA and protein levels were elevated in cervical squamous cell cancer and the elevated cytoplasmic expression of PTK6 was associated with tumor grade and short patient survival. PMID: 27311570
7. PELP1 interacted with GR to activate Brk expression. PMID: 26825173
8. PTK6 prolongs S-phase and increases the ability of gemcitabine to cause DNA damage in vitro and in vivo PMID: 26013168
9. BRK expression in a majority of CC can interact with RTK, augmenting growth and interfering with proliferation inhibitors (SAM68). Therapeutically targeting BRK function (in addition to RTK) should be of benefit for CC treatment. PMID: 25770659
10. Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression PMID: 25241146
11. Establishment of cross talk between PTK6 and CagA by functional studies may further elucidate the underlying biology of H. pylori-mediated gastric cancer PMID: 25838168
12. PTK6 is expressed in the normal human mammary gland, but does not appear to be active and may have kinase-independent functions that are distinct from its cancer promoting activities at the membrane. PMID: 25153721
13. Down-regulated expression of PTK6 is correlated with poor survival in esophageal squamous cell carcinoma. PMID: 25377660
14. PTP1B inhibited BRK by dephosphorylating Tyr-342, but activated SRC by antagonizing PAG-dependent inhibition by CSK. PMID: 25897081
15. Activating mutations in BRK in breast cancer may disrupt intramolecular interactions that normally maintain BRK in an autoinhibited conformation. PMID: 25940761
16. This study shows that Brk phosphorylates p27KIP1, regulating the activity of cyclin D-cyclin-dependent kinase 4. PMID: 25733683
17. Hypoxia-induced PTK6 stabilization and subcellular re-localization to the plasma membrane include increased cell motility and invasion, suggesting PTK6 targeting as a therapeutic approach to reduce hypoxia-regulated metastatic potential. PMID: 25019382
18. PTK6 regulates cellular migration and invasion in pancreatic cancer via ERK signaling. PTK6 may be a novel therapeutic target for pancreatic cancer. PMID: 24788754
19. BRK has a role in targeting Dok1 for ubiquitin-mediated proteasomal degradation and in promoting cell proliferation and migration PMID: 24523872
20. Degradation of Brk involved a calpain-1-mediated proteolytic pathway and indicated an inverse relationship between the level of HER2 expression and calpain-1 activity. PMID: 23707532
21. Protein tyrosine kinase 6 may have a role in poor prognosis and metastasis of nasopharyngeal carcinoma PMID: 23758975
22. Highly active PTK6 promoted epithelial-mesenchymal transition by enhancing activation of AKT, thereby stimulating cancer cell migration and metastases in xenograft models of prostate cancer. PMID: 23856248
23. High PTK6 expression is associated with hypoxia-associated breast cancer progression. PMID: 23928995
24. an important role for PTP1B as a negative regulator of BRK and IGF-1Rbeta signaling in ovarian cancer cells. PMID: 23814047
25. Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT. PMID: 23027128
26. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition. PMID: 23291984
27. present findings indicated that cytoplasmic PTK6 expression is a potential prognostic factor for survival in LSCC patients. High expression of PTK6 was associated with favorable OS and DFS in LSCC patients PMID: 23497344
28. These results provide evidence for a novel mechanism demonstrating the oncogenic potential of PTK6 through degradation of c-Cbl, which is an E3 ligase important in down-regulation of oncoproteins. PMID: 23352614
29. Knockdown of PTK6 enhances apoptosis in HCT116 cells with wild-type p53. PMID: 22989419
30. breast tumor kinase (Brk)/protein-tyrosine kinase 6 (PTK6), a nonreceptor protein-tyrosine kinase highly expressed in most human breast tumors, interacted with EGFR and sustained ligand-induced EGFR signaling. PMID: 22231447
31. Brk expression in human breast tumors may contribute to progression by inducing p38-driven pro-survival signaling pathways. PMID: 21923922
32. results demonstrate that Hsp90 plays an essential role in regulating PTK6 stability and suggest that Hsp90 inhibitors may be useful as therapeutic drugs for PTK6-positive cancers, including breast cancer PMID: 22849407
33. PTK6 was identified as a transcript that is down-regulated in human esophageal squamous cell carcinoma via epigenetic modification at the PTK6 locus. PMID: 22705009
34. Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3. PMID: 22547065
35. a novel function for PTK6 at the plasma membrane PMID: 22084245
36. show that as primary human keratinocytes are induced to differentiate in vitro, Brk levels decrease PMID: 21240512
37. present findings indicate an increase of cytoplasmic Brk expression in non-small cell lung cancer PMID: 21603980
38. Data suggest that since PTK6 plays an important role in HER receptor signal transduction, its down-regulation might be suitable for future therapy approaches in breast cancer. PMID: 21380407
39. Alternative transcript-PTK6 is able to negatively regulate growth and modulate PTK6 activity, protein-protein associations and/or subcellular localization. PMID: 21479203
40. Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells. PMID: 20929863
41. Brk antagonizes the transcriptional activity of the transcription factor FoxO family of proteins by inhibiting its nuclear localization. As a result, the cell cycle inhibitor p27, a FoxO target gene, is down-regulated. PMID: 20162673
42. PTK6 enhances EGFR signaling by inhibition of EGFR down-regulation through phosphorylation of ARAP1 in breast cancer cells. PMID: 20554524
43. AKT is a direct substrate of PTK6 and AKT tyrosine residues 315 and 326 are phosphorylated by PTK6. PMID: 20606012
44. PTK6 associates with nuclear and cytoplasmic beta-catenin and inhibits beta-catenin- and T-cell factor (TCF)-mediated transcription. PMID: 20026641
45. the effect of Sam68 was inhibited in a dose-dependent manner by coexpression of an activated form of the nuclear kinase Sik/BRK that hyperphosphorylated Sam68 PMID: 12482964
46. The tyrosine kinases Brk/PTK6/Sik, Srm, Frk/Rak/Gtk/Iyk/Bsk, and Src42A/Dsrc41 have a low degree of sequence homology to other known kinases. The exon structure of these kinases, called the Brk family, is highly conserved and distinct. PMID: 12725532
47. BRK plays a role in differentiation of prostate epithelial cells PMID: 12833144
48. Study suggests that SH3 interactions will govern phosphorylation of many substrates by BRK. PMID: 14676834
49. Results describe the solution structure and backbone dynamics of the human protein-tyrosine kinase-6 Src homology 2 (SH2) domain using multidimensional NMR spectroscopy. PMID: 15056653
50. in breast cancer cells breast tumor kinase (Brk) behaves similarly to a constitutively active Brk mutant (YF-Brk) and associates with tyrosine-phosphorylated proteins in deregulated signaling complexes PMID: 15539407
顯示更多

收起更多
亞細胞定位：

Cytoplasm. Nucleus. Cell projection, ruffle. Membrane. Note=Colocalizes with KHDRBS1, KHDRBS2 or KHDRBS3, within the nucleus. Nuclear localization in epithelial cells of normal prostate but cytoplasmic localization in cancer prostate.
蛋白家族：

Protein kinase superfamily, Tyr protein kinase family, BRK/PTK6/SIK subfamily
組織特異性：

Epithelia-specific. Very high level in colon and high levels in small intestine and prostate, and low levels in some fetal tissues. Not expressed in breast or ovarian tissue but expressed in high percentage of breast and ovarian cancers. Also overexpresse
數據庫鏈接：

HGNC: 9617

OMIM: 602004

KEGG: hsa:5753

STRING: 9606.ENSP00000217185

UniGene: Hs.51133

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human